Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck

K. J. Harrington, C. Lewanski, A. D. Northcote, J. Whittaker, A. M. Peters, R. G. Vile, J. S.W. Stewart

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

A phase II trial of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy was conducted in 20 patients with treatment-naïve squamous cell cancer of the head and neck (SCCHN). 10 patients received two cycles of Caelyx™ (40 mg/m2) every 3 weeks before starting radical radiotherapy (RT). Subsequently, consecutive groups of 3 patients received a third escalating dose of Caelyx™ (10, 15 and 20 mg/m2) 3 days before RT. 9 of 18 (50%, 95% confidence intervals (CI): 26-74%) evaluable patients responded to Caelyx™, with 11 responses in 26 (42%, 95% CI: 24-62%) evaluable sites (three complete responses (12%), eight partial responses (31%)). There was no grade 3/4 haematological, mucosal or cardiac toxicity. Nausea and vomiting were minimal. There were no drug-related RT delays. Local RT-induced toxicity was not increased. Caelyx™ has significant activity against SCCHN and warrants further investigation in this disease. In view of its tumour targeting properties and activity at moderate doses, it may be useful in concomitant chemoradiotherapy strategies for SCCHN.

Original languageEnglish (US)
Pages (from-to)2015-2022
Number of pages8
JournalEuropean Journal of Cancer
Volume37
Issue number16
DOIs
StatePublished - Oct 16 2001

Keywords

  • Doxorubicin
  • Head and neck cancer
  • Pegylated liposome
  • Radiotherapy
  • Response
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck'. Together they form a unique fingerprint.

  • Cite this